Localized Injection-site Toxic Erythema of Chemotherapy: An Under-recognized Acquaintance Revisited
DOI:
https://doi.org/10.2340/00015555-3791Keywords:
toxic erythema of chemotherapy, localized epidermal necrolysis, cytostatic drugs, chemotherapy adverse effect, chemotherapy skin eruption, drug reactionAbstract
Abstract is missing (Short communication)
Downloads
References
Bolognia JL, Cooper DL, Glusac EJ. Toxic erythema of chemotherapy: a useful clinical term. J Am Acad Dermatol 2008; 59: 524-529.
DOI: https://doi.org/10.1016/j.jaad.2008.05.018
Reyes-Habito CM, Roh EK. Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer: Part II. Targeted therapy. J Am Acad Dermatol 2014; 71: 217.e1-217.e11.
DOI: https://doi.org/10.1016/j.jaad.2014.04.013
Sanmartin O, Beato C, Suh-Oh HJ, Aragon I, Espana A, Majem M, et al. Clinical management of cutaneous adverse events in patients on chemotherapy: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology. Actas Dermosifiliogr 2019; 110: 448-459.
DOI: https://doi.org/10.1016/j.adengl.2019.05.003
Sibaud V, Fricain JC, Baran R, Robert C. Pigmentary disorders induced by anticancer agents. Part I: Chemotherapy. Ann Dermatol Venereol 2013; 140: 183-196.
DOI: https://doi.org/10.1016/j.annder.2012.12.012
Sibaud V. Toxic erythema of chemotherapy. Ann Dermatol Venereol 2015; 142: 81-84.
DOI: https://doi.org/10.1016/j.annder.2014.09.021
Reynolds PM, MacLaren R, Mueller SW, Fish DN, Kiser TH. Management of extravasation injuries: a focused evaluation of noncytotoxic medications. Pharmacotherapy 2014; 34: 617-632.
DOI: https://doi.org/10.1002/phar.1396
Upton J, Mulliken JB, Murray JE. Major intravenous extravasation injuries. Am J Surg 1979; 137: 497-506.
DOI: https://doi.org/10.1016/0002-9610(79)90121-1
Arias D, Requena L, Hasson A, Gutierrez M, Domine M, Martin L, et al. Localized epidermal necrolysis (erythema multiforme-like reaction) following intravenous injection of vinblastine. J Cutan Pathol 1991; 18: 344-346.
DOI: https://doi.org/10.1111/j.1600-0560.1991.tb01547.x
Chew L, Chuen VSL. Cutaneous reaction associated with weekly docetaxel administration. J Oncol Pharm Pract 2009; 15: 29-34.
DOI: https://doi.org/10.1177/1078155208096111
Chu CY, Yang CH, Yang CY, Hsiao GH, Chiu HC. Fixed erythrodysaesthesia plaque due to intravenous injection of docetaxel. Br J Dermatol 2000; 142: 808-811.
DOI: https://doi.org/10.1046/j.1365-2133.2000.03432.x
Geddes ERC, Cohen PR. Antineoplastic agent-associated serpentine supravenous hyperpigmentation: superficial venous system hyperpigmentation following intravenous chemotherapy. South Med J 2010; 103: 231-235.
DOI: https://doi.org/10.1097/SMJ.0b013e3181ce0f5e
Ghosh SK, Bandyopadhyay D, Ghoshal L, Basu S. Letter: docetaxel-induced supravenous serpentine dermatitis. Dermatol Online J 2011; 17: 16.
Marcoux D, Anex R, Russo P. Persistent serpentine supravenous hyperpigmented eruption as an adverse reaction to chemotherapy combining actinomycin and vincristine. J Am Acad Dermatol 2000; 43: 540-546.
DOI: https://doi.org/10.1067/mjd.2000.106239
Lang K, Groeger M, Neumann NJ, Ruzicka T, Fritsch C. Supravenous hyperpigmentation, transverse leuconychia and transverse melanonychia after chemotherapy for Hodgkin's disease. J Eur Acad Dermatol Venereol 2002; 16: 162-163.
DOI: https://doi.org/10.1046/j.1468-3083.2002.00424.x
Chan C-C, Lin S-J. Images in clinical medicine. Serpentine supravenous hyperpigmentation. N Engl J Med 2010; 363: e8.
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2021 Elisa Ríos-Viñuela, Eduardo Bernia, Tomás Toledo-Pastrana, Celia Requena, Adrián Diago, Carlos Serra-Guillén, Beatriz Llombart, Victor Traves, Eduardo Nagore, Carlos Guillén, Onofre Sanmartin
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
